Study to Assess the Efficacy, Safety and Tolerability of (iTind)

Inclusion Criteria: * Male with AUR secondary to BPO * Age ≥40 years * Acute urinary retention with at least one failed trial without catheter (TWOC) while on alpha blocker * Ability to sign an informed consent form * Prostate volume \<80 ml * Life expectancy \>1 year. Exclusion Criteria: * Suspected malignant disease of the lower urinary tract including prostate or bladder cancer * Chronic retention of urine with history of either retention volume greater than one liter or upper tract obstruction * Known neurogenic bladder * Immunosuppression * Suspected urethral strictures, bladder neck contracture, Urinary bladder stones * An obstructive or protruding median lobe of the prostate * An active symptomatic urinary tract infection * Enrolled in another treatment trial for any disease * Previous pelvic irradiation or radical pelvic surgery * Any previous prostate surgery.